Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25840693

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 May
First author
Eggermont AM

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):478-80. doi: 10.1016/S1470-2045(15)70162-2.
    note
    Source null
    related pmid
    25840692
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70271-8.
    note
    Source null
    related pmid
    26065611
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2016 Jun;17(6):e223. doi: 10.1016/S1470-2045(16)30139-5.
    note
    Source null
    related pmid
    27299277
    relationship
    Erratum in

Authors and identifiers

  1. name
    Eggermont AM
    type
    Author
  2. name
    Chiarion-Sileni V
    type
    Author
  3. name
    Grob JJ
    type
    Author
  4. name
    Dummer R
    type
    Author
  5. name
    Wolchok JD
    type
    Author
  6. name
    Schmidt H
    type
    Author
  7. name
    Hamid O
    type
    Author
  8. name
    Robert C
    type
    Author
  9. name
    Ascierto PA
    type
    Author
  10. name
    Richards JM
    type
    Author
  11. name
    Lebbé C
    type
    Author
  12. name
    Ferraresi V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Eggermont AM
    type
    Author
  2. name
    Chiarion-Sileni V
    type
    Author
  3. name
    Grob JJ
    type
    Author
  4. name
    Dummer R
    type
    Author
  5. name
    Wolchok JD
    type
    Author
  6. name
    Schmidt H
    type
    Author
  7. name
    Hamid O
    type
    Author
  8. name
    Robert C
    type
    Author
  9. name
    Ascierto PA
    type
    Author
  10. name
    Richards JM
    type
    Author
  11. name
    Lebbé C
    type
    Author
  12. name
    Ferraresi V
    type
    Author
bibliography ids
  1. nci-bib-7d60fff0c9c05dc0285235bf
book metadata
content sha256
7bd3bd9701e2ed0fab8bb44a9211e939f7ec2b2b8bb5095981ae3b0863efa06b
document type
citation
dois
  1. 10.1016/S1470-2045(15)70122-1
electronic publication date
display
2015 Mar 31
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:25840693
immutable id
pubmed:25840693@7bd3bd9701e2ed0fab8bb44a9211e939f7ec2b2b8bb5095981ae3b0863efa06b
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
522-30
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):478-80. doi: 10.1016/S1470-2045(15)70162-2.
    note
    Source null
    related pmid
    25840692
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70271-8.
    note
    Source null
    related pmid
    26065611
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2016 Jun;17(6):e223. doi: 10.1016/S1470-2045(16)30139-5.
    note
    Source null
    related pmid
    27299277
    relationship
    Erratum in
outcomes validated
false
pmid
25840693
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
c05852d607ee9dd6327514b400e6f1017b93762115043e72634402b89a71ddae
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 May
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25840693/
title
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Preserved source evidence · Not medical advice